Press Releases

Year

August 8, 2018

CytomX Therapeutics Announces Second Quarter 2018 Financial Results

- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - - Preliminary Proof-of-Concept for Probody™ Platform and CX-072 - SOUTH SAN FRANCISCO, Calif. , Aug.

August 7, 2018

CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

July 30, 2018

CytomX Therapeutics to Announce Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, plans to

July 17, 2018

CytomX Therapeutics Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 17, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

July 12, 2018

CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

July 10, 2018

CytomX Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

June 14, 2018

CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel

Brings 25 Years of Biotechnology and Pharmaceutical Legal Leadership Experience SOUTH SAN FRANCISCO, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

June 4, 2018

CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody™ Platform and CX-072 at 2018 ASCO Annual Meeting

– PD-L1 Targeting Probody CX-072 Well Tolerated and Shows Antitumor Activity as Monotherapy and in Combination with Ipilimumab – – Company to Host Conference Call and Webcast Today Monday, June 4 th at 5:00 p.m. CT / 6:00 p.m. ET – SOUTH SAN FRANCISCO, Calif.

June 1, 2018

CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today

May 31, 2018

CytomX to Present at the Jefferies 2018 Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

CytomX

Xciting things are happening here

Press Releases

Press Releases

Investor Tools